Observational Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3852-3859
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3852
Table 1 Expression of integrin αvβ6 and MMP-9 and patient characteristics
CharacteristicNo.αvβ6
P valueMMP-9
P value
NegativePositiveNegativePositive
Age (yr)
< 605133183120
> 607549260.94242330.593
Gender
Male7850284335
Female4832160.76930180.416
Location
Upper272071611
Middle5128232823
Lower4834140.13629190.847
Lauren type
Intestinal8347364637
Diffuse433580.00627160.427
Differentiation
Well19154613
Moderate3014161812
Poor7753240.03849280.039
T stage
T114104311
T2137685
T318108144
T48155260.57848330.014
N stage
N03726111819
N117125107
N22610161115
N34634120.01634120.033
M stage
M012481437351
M12110.652020.094
TNM stage
I124839
II423662220
III7041294822
IV2110.002020.008
Table 2 Expression correlation of integrin αvβ6 and MMP-9
αvβ6 expressionMMP-9 expression
Total
NegativePositive
Negative562682
Positive172744
Total7353126
Table 3 Univariate and multivariate analyses comparing overall survival to prognostic factors in 126 gastric cancer patients
FactorsUnivariate analysis
Multivariate analysis
Relative risk (95%CI)P valueRelative risk (95%CI)P value
Age (yr)
< 601
> 601.800 (1.090-2.973)0.258
Gender
Female1
Male1.450 (0.882-2.381)0.143
Location
Upper1
Middle/Lower1.171 (0.856-1.602)0.323
Lauren type
Intestinal1
Diffuse1.836 (1.061-3.177)0.031.431 (0.805-2.545)0.222
Differentiation
Well1
Moderate/Poor1.045 (0.764-1.429)0.784
T stage
T111
T2-41.295 (1.006-1.668)0.0501.248 (0.813-1.916)0.311
N stage
N011
N1-31.343 (1.105-1.633)0.0031.249 (0.818-1.909)0.303
M stage
M011
M126.25 (2.887-238.81)0.0048.555 (0.735-99.62)0.087
TNM stage
I11
II-IV2.314 (1.502-3.565)< 0.0011.654 (0.643-4.257)0.296
αvβ6
Negative11
Positive2.862 (1.452-3.747)< 0.0012.632 (1.569-4.416)0.003
MMP-9
Negative11
Positive2.193 (1.110-2.787)0.0051.813 (1.398-2.351)0.007